+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer



A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer



Gynecologic Oncology 134(3): 468-472



To compare survival outcomes for patients with advanced epithelial ovarian cancer (EOC) who received primary intravenous/intraperitoneal (IV/IP) chemotherapy to those who received IV followed by consolidation (treatment given to patients in remission) IP chemotherapy. Data were analyzed and compared for all patients with stage III-IV EOC who underwent optimal primary cytoreduction (residual disease ≤ 1 cm) followed by cisplatin-based consolidation IP chemotherapy (1/2001-12/2005) or primary IV/IP chemotherapy (1/2005-7/2011). We identified 224 patients; 62 (28%) received IV followed by consolidation IP chemotherapy and 162 (72%) received primary IV/IP chemotherapy. The primary IP group had significantly more patients with serous tumors. The consolidation IP group had a significantly greater median preoperative platelet count, CA-125, and amount of ascites. There were no differences in residual disease at the end of cytoreduction between both groups. The median progression-free survival (PFS) was greater for the primary IP group; however, this did not reach statistical significance (23.7 months vs 19.7 months; HR 0.78; 95% CI, 0.57-1.06; p=0.11). The median overall survival (OS) was significantly greater for the primary IP group (78.8 months vs 57.5 months; HR 0.56; 95% CI, 0.38-0.83; p=0.004). On multivariate analysis, after adjusting for confounders, the difference in PFS was not significant (HR 0.78; 95% CI, 0.56-1.11; p=0.17), while the difference in OS remained significant (HR 0.59; 95% CI, 0.39-0.89; p=0.01). In our study, primary IV/IP chemotherapy was associated with improved OS compared to IV followed by consolidation IP chemotherapy in patients with optimally cytoreduced advanced EOC.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 051112102

Download citation: RISBibTeXText

PMID: 25042672

DOI: 10.1016/j.ygyno.2014.07.090


Related references

A Comparison of Primary Intraperitoneal Chemotherapy to Consolidation Intraperitoneal Chemotherapy in Optimally Resected Advanced Ovarian Cancer. Obstetrical & Gynecological Survey 69(12): 741-742, 2014

Long-Term Survival Analysis of Intraperitoneal versus Intravenous Chemotherapy for Primary Ovarian Cancer and Comparison between Carboplatin- and Cisplatin-based Intraperitoneal Chemotherapy. Journal of Korean Medical Science 32(12): 2021-2028, 2017

Patient with Brca mutations have superior outcomes after intraperitoneal chemotherapy in optimally resected ovarian cancer. Gynecologic Oncology 149: 205-206, 2018

Patients with BRCA mutations have superior outcomes after intraperitoneal chemotherapy in optimally resected high grade ovarian cancer. Gynecologic Oncology 151(3): 477-480, 2018

Intraperitoneal chemotherapy requires expertise and should be the standard of care for optimally surgically resected epithelial ovarian cancer patients. Annals of Oncology 24(Suppl. 10): X41-X45, 2013

Report of nationwide questionnaire: intraperitoneal chemotherapy for advanced ovarian cancer based on clinical results--reports of 5th "Gynecologic Intraperitoneal Chemotherapy Study Group" meeting. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 23(10): 1305-1311, 1996

Intraperitoneal chemotherapy for optimally debulked advanced ovarian cancer: a new standard in patient care?. Clinical and Translational Oncology 9(7): 409-411, 2007

Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. Journal of Clinical Oncology 26(25): 4144-4150, 2008

Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer?. Annals of Oncology 28(Suppl_8): Viii40-Viii45, 2017

Does intraperitoneal chemotherapy benefit optimally debulked epithelial ovarian cancer patients after neoadjuvant chemotherapy?. Gynecologic Oncology 121(3): 451-454, 2011

Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma. Gynecologic Oncology 83(2): 198-204, 2001

Long-term survival with consolidation intraperitoneal chemotherapy (IP) in advanced ovarian cancer (AOC) with complete pathological remission. European Journal of Cancer 37: S320-S321, 2001

Neoadjuvant chemotherapy, interval debulking surgery , and intraperitoneal consolidation Impact on survival in advanced ovarian cancer. Gynecologic Oncology 52(1): 106, 1994

Long-term survival with consolidation intraperitoneal chemotherapy in advanced ovarian cancer with complete pathological remission. European Journal of Cancer 37(Suppl. 6): S320-S321, 2001

Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center. Gynecologic Oncology 142(1): 13-18, 2016